S&P 500   3,608.51 (-0.88%)
DOW   28,888.81 (-1.15%)
QQQ   270.37 (-0.55%)
AAPL   140.36 (-1.49%)
MSFT   235.65 (-0.78%)
META   137.34 (+0.68%)
GOOGL   96.79 (-0.65%)
AMZN   114.77 (-0.03%)
TSLA   267.54 (-0.25%)
NVDA   123.42 (+1.00%)
NIO   15.91 (+2.12%)
BABA   80.66 (+2.02%)
AMD   64.24 (+0.16%)
T   15.45 (-0.52%)
MU   51.18 (+2.34%)
CGC   2.79 (+0.36%)
F   11.31 (-1.39%)
GE   62.46 (-0.43%)
DIS   95.77 (-1.72%)
AMC   7.15 (+0.70%)
PYPL   87.29 (-1.59%)
PFE   44.16 (+0.00%)
NFLX   239.79 (+0.03%)
S&P 500   3,608.51 (-0.88%)
DOW   28,888.81 (-1.15%)
QQQ   270.37 (-0.55%)
AAPL   140.36 (-1.49%)
MSFT   235.65 (-0.78%)
META   137.34 (+0.68%)
GOOGL   96.79 (-0.65%)
AMZN   114.77 (-0.03%)
TSLA   267.54 (-0.25%)
NVDA   123.42 (+1.00%)
NIO   15.91 (+2.12%)
BABA   80.66 (+2.02%)
AMD   64.24 (+0.16%)
T   15.45 (-0.52%)
MU   51.18 (+2.34%)
CGC   2.79 (+0.36%)
F   11.31 (-1.39%)
GE   62.46 (-0.43%)
DIS   95.77 (-1.72%)
AMC   7.15 (+0.70%)
PYPL   87.29 (-1.59%)
PFE   44.16 (+0.00%)
NFLX   239.79 (+0.03%)
S&P 500   3,608.51 (-0.88%)
DOW   28,888.81 (-1.15%)
QQQ   270.37 (-0.55%)
AAPL   140.36 (-1.49%)
MSFT   235.65 (-0.78%)
META   137.34 (+0.68%)
GOOGL   96.79 (-0.65%)
AMZN   114.77 (-0.03%)
TSLA   267.54 (-0.25%)
NVDA   123.42 (+1.00%)
NIO   15.91 (+2.12%)
BABA   80.66 (+2.02%)
AMD   64.24 (+0.16%)
T   15.45 (-0.52%)
MU   51.18 (+2.34%)
CGC   2.79 (+0.36%)
F   11.31 (-1.39%)
GE   62.46 (-0.43%)
DIS   95.77 (-1.72%)
AMC   7.15 (+0.70%)
PYPL   87.29 (-1.59%)
PFE   44.16 (+0.00%)
NFLX   239.79 (+0.03%)
S&P 500   3,608.51 (-0.88%)
DOW   28,888.81 (-1.15%)
QQQ   270.37 (-0.55%)
AAPL   140.36 (-1.49%)
MSFT   235.65 (-0.78%)
META   137.34 (+0.68%)
GOOGL   96.79 (-0.65%)
AMZN   114.77 (-0.03%)
TSLA   267.54 (-0.25%)
NVDA   123.42 (+1.00%)
NIO   15.91 (+2.12%)
BABA   80.66 (+2.02%)
AMD   64.24 (+0.16%)
T   15.45 (-0.52%)
MU   51.18 (+2.34%)
CGC   2.79 (+0.36%)
F   11.31 (-1.39%)
GE   62.46 (-0.43%)
DIS   95.77 (-1.72%)
AMC   7.15 (+0.70%)
PYPL   87.29 (-1.59%)
PFE   44.16 (+0.00%)
NFLX   239.79 (+0.03%)
OTCMKTS:ARTH

Arch Therapeutics - ARTH Stock Forecast, Price & News

$0.02
0.00 (-21.00%)
(As of 09/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.0151
$0.0195
50-Day Range
$0.02
$0.05
52-Week Range
$0.01
$0.14
Volume
511,202 shs
Average Volume
956,329 shs
Market Capitalization
$3.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ARTH stock logo

About Arch Therapeutics (OTCMKTS:ARTH) Stock

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

Arch Therapeutics Launches Experts in Wound Care Program
Arch Therapeutics Provides Corporate Update
Arch Therapeutics to Present at the LD Micro Main Event
See More Headlines
Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Company Calendar

Last Earnings
7/23/2020
Today
9/30/2022
Fiscal Year End
9/30/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
$-6,240,000.00
Net Margins
-35,372.46%
Pretax Margin
-35,372.46%

Debt

Sales & Book Value

Annual Sales
$10,000.00

Miscellaneous

Free Float
225,697,000
Market Cap
$3.95 million
Optionable
Not Optionable
Beta
-0.07

Key Executives

  • Dr. Terrence W. Norchi M.D. (Age 57)
    Co-Founder, Chairman, Pres, CEO & Sec.
    Comp: $477.53k
  • Mr. Michael S. Abrams (Age 52)
    Chief Financial Officer
    Comp: $345.04k
  • Mr. Daniel M. Yrigoyen (Age 53)
    VP of Sales
    Comp: $291.73k
  • Dr. Rutledge Ellis-Behnke Ph.D.
    Co-Founder & Scientific Advisor
  • Dr. Steven A. Kates Ph.D.
    VP of Technology
  • Mr. Daniel C. Wadsworth Jr. (Age 68)
    Advisor & Consultant of Wound Care Commercialization













ARTH Stock - Frequently Asked Questions

How have ARTH shares performed in 2022?

Arch Therapeutics' stock was trading at $0.0950 at the beginning of the year. Since then, ARTH shares have decreased by 83.4% and is now trading at $0.0158.
View the best growth stocks for 2022 here
.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01.

What other stocks do shareholders of Arch Therapeutics own?
What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.02.

How much money does Arch Therapeutics make?

Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $3.95 million and generates $10,000.00 in revenue each year.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com.

This page (OTCMKTS:ARTH) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.